Analytical-evidence guide · batch-specific reading
Retatrutide COA and Endotoxin Reports: Read RET26 and RET27 Without Mixing the Batches
A purity percentage is not an endotoxin result, and a report for one Retatrutide batch cannot automatically describe another. This guide keeps the four report links and two batch records distinct.
Four report links, two different batches
Growth Guys presents separate purity-and-mass and endotoxin report links for its Retatrutide 10mg and 20mg product pages. The 10mg listing identifies batch RET26; the 20mg listing identifies batch RET27.
The merchant-visible summaries report RET26 at 99.82% average purity and 10.69 mg average mass, with an endotoxin result shown as 1 EU/vial. RET27 is shown at 99.53% average purity and 21.49 mg average mass, with an endotoxin result shown as 12.439 EU/vial. These are separate product panels and separate reported samples.
- RET26: Retatrutide 10mg; purity-and-mass test August 21, 2026; endotoxin test August 24, 2026.
- RET27: Retatrutide 20mg; purity-and-mass test August 31, 2026; endotoxin test September 2, 2026.
- The merchant upload dates and report links should be read alongside the named batch and test category.
Why purity and endotoxin answer different questions
Purity and mass describe measurements defined by the laboratory’s method and the submitted sample. Neither percentage purity nor milligram mass is an endotoxin result.
Endotoxin is reported in a different unit, such as EU/vial. It cannot be subtracted from a purity percentage or compared numerically with mass. An endotoxin result also does not establish sterility, absence of every contaminant, medical approval, or suitability for a particular use.
Why RET26 cannot answer a question about RET27
RET26 is the named batch on the 10mg listing and RET27 is the named batch on the 20mg listing. Their reported values and dates differ. That difference is not proof that either product is better or worse; it shows why the relevant product, batch identifier, report category, and test date must be matched before drawing a conclusion.
A report archive is a discovery resource, not a substitute for inspecting the document connected to the exact item or batch under review. Even matching printed identifiers do not, by themselves, establish chain of custody for every unit sold.
A careful source check
Start with the current merchant product page. Record the named batch and identify whether the link is for purity and mass or for endotoxin. Open the original laboratory link and compare the sample name, task identifier, dates, units, result wording, and any qualifier such as a less-than sign.
If an issuer page is not fully readable in the review, say so. Do not silently treat a merchant summary as an independently rerun laboratory analysis, and do not turn the absence of a field in one summary into proof that the test was or was not performed elsewhere.
Keep test date, merchant upload date, and editorial review date separate. None of those dates is a daily re-test of the underlying sample.
Where VIP10 checkout evidence fits
VIP10 cart evidence answers a pricing question, not a laboratory question. A dated cart observation can document a code response and visible discount before payment; it does not establish purity, endotoxin status, sterility, current stock, or product suitability.
Readers should use the current VIP10 record for the latest code observation and the merchant’s laboratory-results pages for batch-specific documents. Keeping those evidence types separate makes each claim narrower and easier to inspect.
Sources and scope
Merchant product panels: Retatrutide 10mg and Retatrutide 20mg. The merchant links to separate issuing-laboratory tasks for each purity-and-mass and endotoxin report. The figures in this guide are the merchant-visible summaries; this page does not claim to have independently rerun the laboratory analyses.
This is an evidence-literacy guide, not a product recommendation, dosing guide, health assessment, or statement of medical authorization.